Welcome to our dedicated page for Bio-Techne SEC filings (Ticker: TECH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bio-Techne Corporation filings document the formal disclosure record for a Minnesota life sciences company that sells reagents, analytical instruments and precision diagnostics. Recent Form 8-K reports furnish quarterly and annual operating results, financial condition updates and cash dividend announcements, with exhibits containing the related earnings and dividend releases.
Governance filings include definitive proxy materials and annual meeting vote results covering board size and director elections. Other current reports disclose executive leadership changes and employment arrangements for segment management, tying corporate governance disclosures to Bio-Techne's diagnostics, spatial biology and analytical solutions operations.
Bio-Techne Corporation reported mixed third quarter fiscal 2026 results. Net sales were $311.4 million, down 2% year over year, with organic revenue also declining 2% as prior-year GMP fast-track orders and timing of large Commercial Supply shipments weighed on growth.
GAAP earnings improved sharply, with diluted EPS rising to $0.32 from $0.14, driven by a 95% increase in GAAP operating income to $75.5 million and a higher 24.2% operating margin helped by profitability initiatives and the Exosome Diagnostics divestiture. On a non-GAAP basis, adjusted EPS slipped to $0.53 from $0.56 and adjusted operating margin eased to 34.2% from 34.9%.
The Protein Sciences segment posted revenue of $226.2 million, down 1%, with organic revenue down 4%, while Diagnostics and Spatial Biology revenue declined 4% to $85.6 million but delivered 3% organic growth and margin expansion. The company ended the period with $209.8 million in cash and equivalents and reduced long-term debt to $200 million. The Board declared a quarterly cash dividend of $0.08 per share, payable May 29, 2026 to shareholders of record on May 18, 2026.
Bio-Techne Corp executive Steven C. Crouse reported routine equity compensation activity involving company stock. On May 1, 2026, he exercised 794 Restricted Stock Units, which converted into an equal number of Bio-Techne common shares.
To cover tax obligations, 311 common shares were disposed of through a tax-withholding transaction, a non-market event that does not represent an open-market sale. Following these transactions, Crouse directly holds 6,688 shares of common stock, alongside multiple option and restricted stock unit awards that vest over several future dates.
Bio-Techne Corp reports that Vanguard Capital Management beneficially owns 11,559,571 shares of Common Stock, representing 7.38% of the class. The filing states Vanguard exercises sole dispositive power over 11,559,571 shares and sole voting power over 1,379,862 shares. The filing attributes ownership to Vanguard Capital Management and affiliated Vanguard entities per SEC Release No. 34-39538.
Bio-Techne Corp Chief Executive Officer Kim Kelderman reported compensation-related equity activity, not open-market trading. On April 22, 2026, Kelderman exercised stock options to acquire 11,344 shares of Bio-Techne common stock, while 1,363 shares were disposed of to cover tax obligations at $58.58 per share. This left Kelderman with 63,058 common shares held directly after these transactions.
The filing also lists substantial remaining equity incentives, including multiple tranches of stock options and restricted stock units tied to vesting schedules and performance goals, with option exercise prices ranging from $47.60 to $120.46 and expirations extending to August 15, 2035.
Bio-Techne Corporation CFO James Hippel reported routine equity compensation activity. On April 22, 2026, he exercised stock options to acquire 62,000 shares of common stock at an exercise price of $47.60 per share. In a related F-code tax-withholding disposition, 56,097 shares of common stock were delivered at $58.58 per share to cover obligations. Following these transactions, Hippel directly owned 204,722 Bio-Techne common shares and retained substantial unexercised stock options and restricted stock units with vesting schedules extending through 2028.
Bio-Techne Corp Chief Executive Officer Kim Kelderman exercised stock options for 36,500 shares of common stock at an exercise price of $47.60 per share. The options were fully exercisable and converted into an equal number of common shares.
To cover tax obligations tied to this transaction, 32,088 shares of common stock were withheld at a price of $58.66 per share, a non-market tax-withholding disposition. After these transactions, Kelderman directly owns 53,077 common shares and retains substantial unexercised stock options and restricted stock units that vest over multiple future dates.
Bio-Techne Corp senior vice president and general counsel Shane Bohnen reported routine equity compensation activity. On April 3, 2026, he exercised restricted stock units into 2,259 shares of common stock. Of these, 740 shares were withheld at $53.13 per share to cover tax obligations, leaving him with 5,904 common shares held directly. He also continues to hold multiple stock option and restricted stock unit awards that can convert into additional Bio-Techne common shares over time.
The Vanguard Group filed Amendment No. 13 to a Schedule 13G/A reporting that it beneficially owns 0 shares (0%) of Bio‑Techne Corp common stock. The filing states an internal realignment effective January 12, 2026 led certain Vanguard subsidiaries to report separately, and the filing is signed on March 26, 2026.
The disclosure lists Vanguard's principal business office in Malvern, Pennsylvania, and confirms no sole or shared voting or dispositive power over the reported shares.
Crouse Steven C. reported acquisition or exercise transactions in this Form 4 filing.
BIO-TECHNE Corp executive Steven C. Crouse reported new equity awards. On March 2, 2026, he received grants of 2,387 Performance Restricted Stock Units, 735 Restricted Stock Units, and 1,911 stock options, all held directly. Each restricted stock unit represents a contingent right to receive one share of BIO-TECHNE common stock, with various vesting dates extending through 2029 tied to service and, for the performance units, achievement of specified goals.
BIO-TECHNE Corp executive Steven C. Crouse, President – Diagnostics & Spatial Biology, filed an initial Form 3 reporting his equity holdings. He directly holds restricted stock units, stock options and common stock, including 6,529 restricted stock units and 5,894 shares of common stock.
The footnotes explain that each restricted stock unit represents a right to receive one share of Bio-Techne common stock, with multiple RSU and option grants vesting in scheduled installments between 2025 and 2029. The filing does not show any new share purchases or sales, only existing awards and their vesting timelines.